News

Innovative “Nanoprobe” Used to Diagnose Multiple Sclerosis

A nanometric sensor — an extremely small probe originally designed to test samples for the presence of herbicides, heavy metals, and pollutants — was experimentally shown to also detect molecules commonly associated with multiple sclerosis. Physicist FĆ”bio de Lima Leite, a professor at the Federal University of SĆ£o Carlos (UFSCar),…

Association Of British Neurologists Releases New Guidelines For Multiple Sclerosis

The Association of British Neurologists (ABN)Ā recently published newĀ guidelines forĀ how Disease Modifying Therapies (DMTs) for relapsing remitting multiple sclerosis should be monitored and prescribed in the United Kingdom, emphasizing theĀ “right treatment at the right time.” There are currently ten DMTs available on the National Health System (NHS) and elevenĀ in…

Canadian Drug Expert Committee Recommends MS Therapy LEMTRADA For Public Coverage

The Canadian Drug Expert Committee (CDEC) recently recommended thatĀ LEMTRADAĀ (alemtuzumab) beĀ included in provincial and other public drug plansĀ for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS). The recommendation was madeĀ through Canada’sĀ Common Drug Review (CDR) and announced in a press releaseĀ by the company that…

LMU Researchers Identify Biomarker BCMA to Measure MS Severity

In a recent study published in the journal Nature Communications, LMU clinicians have clarified the lifespanĀ of antibody-producing cells and have also identified a novel biomarker that could be used to monitor autoimmune conditions such as multiple sclerosis and lupus erythematous. The humoral immune response is mediated byĀ cells…

MS Views and News Hosting Events for MS Community in July

MS Views and News (MSVN), aĀ non-profit organization that works to improveĀ education, advocacy and service to empower and enhance the quality of life of patients who suffer from multiple sclerosisĀ (MS), has announced it will offerĀ a series of educational eventsĀ on different topics throughout the month of July in…

MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients

MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…

Most MS Survey Respondents Favor Legal Marijuana Access For Medical Use

With 26 statesĀ plus the District of Columbia now allowing medical marijuana use, according to a recent North American Research Committee on Multiple Sclerosis (NARCOMS) survey, many people with multiple sclerosis are considering the herb as a therapeutic option. NARCOMS is a research program that allows people with Multiple Sclerosis…

MS Health Care Excellence Awards Launched in UK

UK-basedĀ MS Trust has announced the launch of newĀ awards designedĀ to distinguish healthcare professionals that are committed to treatingĀ and changing the lives of patients who suffer from multiple sclerosis (MS). The QuDos Awards are currently open for nominations and will featureĀ ten different categories. TheĀ QuDoS in MS Awards ā€“…

Novartis Pharma Program Helping Young People with MS Get And Keep Jobs

Most employers these days talk about having workforce diversity oriented policies that support hiring people living with disabilities and chronic diseases, but what distinguishes rhetoric from reality? What in positive, practical terms can companies do in support of helping people living with visible or invisible challenges find and keep gainful…